8-K: Freenome to Go Public via SPAC Merger with Perceptive Capital

Freenome Holdings, Inc., an early cancer detection company, will merge with Perceptive Capital Solutions Corp (PCSC) to become a publicly listed entity on Nasdaq under the ticker FRNM, supported by a $240 million PIPE investment.

Summary

• Freenome Holdings, Inc. (Freenome) and Perceptive Capital Solutions Corp (PCSC) have entered into a definitive business combination agreement.
• Upon closing, PCSC will redomicile as a Delaware corporation, be renamed Freenome, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol FRNM.
• The transaction includes approximately $90 million held in PCSC's trust account (assuming no redemptions by public shareholders) and a $240 million concurrent PIPE financing at $10.00 per share.
• The PIPE is led by Perceptive Advisors and RA Capital, with participation from ADAR1 Capital, Bain Capital Life Sciences, Farallon Capital Management, and other investors.
• Freenome shareholders will roll 100% of their equity into the combined company and will not receive any cash proceeds.
• The combined company is expected to have a post-transaction equity value of approximately $1.1 billion, assuming no redemptions by PCSC's public shareholders.
• Net proceeds from the transaction are expected to provide approximately $330 million (prior to transaction costs) to the combined company.
• The business combination is expected to be completed in the first half of 2026, subject to shareholder and regulatory approvals.
• The transaction is structured as a domestication of PCSC to Delaware, followed by a two-step merger where Freenome becomes a wholly-owned subsidiary of the new public entity.
• An Investor Rights Agreement will grant certain registration rights to holders of New Freenome Common Stock, including demand and piggyback rights.
• A Lock-Up Agreement will restrict transfers of shares by the Sponsor and certain Freenome stockholders for six months post-closing.
• New Freenome will adopt an Equity Incentive Plan reserving 12% of fully-diluted shares and an Employee Stock Purchase Plan reserving 2% of fully-diluted shares, with annual increases for both.

Sentiment

Score: 8

Explanation: The filing outlines a clear path to public listing with substantial funding from reputable investors, strong clinical validation for its lead product, and significant strategic partnerships. The detailed pipeline and technology platform suggest strong future growth potential, despite inherent risks in clinical development and commercialization.

Positives

• The transaction provides Freenome with approximately $330 million in gross proceeds (assuming no redemptions) to accelerate product development, expand commercial infrastructure, and advance its personalized multi-cancer detection pipeline.
• The PIPE financing, led by premier healthcare investors like Perceptive Advisors and RA Capital, validates Freenome's technology and market approach.
• Freenome's technology platform, based on multiomics and AI/ML, is designed for sustainable performance advantages, data moat creation, and rapid test versioning.
• The company's lead product, SimpleScreen CRC v1, has completed a pivotal clinical study (PREEMPT CRC) meeting all primary endpoints and was published in JAMA, with PMA submitted in August 2025.
• A partnership with Exact Sciences for U.S. commercialization of the blood-based CRC test (if approved) provides up to $885 million in value, including a $75 million upfront payment and $700 million in regulatory/market access milestones, accelerating market adoption.
• A partnership with Roche for ex-U.S. development and commercialization of a kitted Personalized MCED test provides up to $209 million, including a $75 million upfront convertible note.
• Freenome retains rights for its CRC blood test when ordered with other screening tests, supporting its multi-cancer early detection strategy.
• The company has a pipeline targeting 10+ cancer indications, covering approximately 65% of all cancer diagnoses and 70% of cancer-related deaths.
• The Lung v1 test has met analytical and clinical performance targets to support a planned LDT launch in 2H 2026, addressing a significant unmet need in lung cancer screening.

Negatives

• The company has incurred significant net losses since its inception and anticipates continued net losses for the coming years.
• Freenome operates in a rapidly evolving field with a limited operating history, making it difficult to evaluate its current business and predict future performance.
• The company may need to raise additional capital beyond this transaction to fund existing operations, develop its platform, commercialize new products, or expand operations.
• There is intense competition from other companies in the early cancer detection market.
• The transaction is subject to PCSC shareholder redemptions, which could reduce the available cash proceeds below the anticipated $330 million.

Risks

• Need to raise additional capital to fund existing operations, develop the platform, commercialize new products, or expand operations.
• Challenges in attracting and retaining qualified personnel due to competitive labor markets, potentially hindering effective management of future growth.
• Loss of the founder, CEO, or other senior management team members could impede business strategy execution.
• Disruptions or changes in funding for the FDA and other government agencies could delay product development, authorization, or commercialization.
• Damage to or inoperability of existing facilities could jeopardize research and development efforts.
• Disruptions in commercial courier delivery services for samples could harm the business.
• International expansion exposes the company to business, regulatory, political, operational, financial, and economic risks.
• Intense competition from other companies may prevent successful competition.
• Inability to implement and maintain effective internal controls over financial reporting could lead to investor loss of confidence and adverse stock price effects.
• Clinical development is a lengthy, expensive process with uncertain outcomes, and earlier study results may not be predictive of future results.
• Delays in or failure to obtain required FDA clearances or approvals for products, or improvements/expanded indications, could materially delay or prevent commercialization.
• The use of Artificial Intelligence presents new risks and challenges to the business.
• Products, if approved, may be subject to recalls, leading to adverse impact on reputation, product liability suits, or costly investigations/fines.
• Interim, 'topline,' and preliminary clinical study data may change as more patient data become available and are subject to audit/verification.
• The size of the market for each product, if approved, has not been established with precision and may be smaller than estimated.
• Products, if approved, may fail to achieve necessary market acceptance for commercial success.
• Inability to successfully market, sell, or distribute products, or expand the sales organization, could adversely affect the business.
• Reliance on a limited number of suppliers or sole suppliers for products and materials poses risks if replacements or transitions are not possible.
• Failure to comply with healthcare and other applicable laws and regulations could result in substantial penalties and adverse effects on business, reputation, and financial condition.
• Inadequate coverage or reimbursement from third-party payers (commercial and government) for tests would negatively affect business and results of operations.
• Business activities are subject to FCPA and similar anti-bribery and anti-corruption laws, with non-compliance leading to penalties.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Employees, principal investigators, consultants, and commercial partners may engage in misconduct or improper activities, including non-compliance with regulatory standards and insider trading.
• 'Research use only' and 'investigational use only' products could become subject to more onerous regulation, increasing costs and delaying commercialization.
• Inability to obtain and maintain intellectual property protection, or insufficient scope of protection, could allow third parties to develop similar technologies.
• Failure to protect the confidentiality of trade secrets could materially adversely affect technology value.
• Litigation or other proceedings related to intellectual property infringement are costly and time-consuming.
• Inability to protect or enforce intellectual property rights adequately throughout the world.
• Issued patents could be found invalid or unenforceable if challenged.
• Developments in patent law could negatively impact the business.
• Non-compliance with procedures for obtaining and maintaining patent protection could reduce or eliminate protection.
• Inadequate protection of trademarks and trade names could hinder name recognition.
• Collection, use, and disclosure of personal information is subject to privacy and security laws, with non-compliance leading to liability or reputational harm.
• Cybersecurity incidents could compromise sensitive information, prevent data access, and expose the company to substantial liability.
• Stock price has fluctuated and may fluctuate significantly as a public company.
• Future sales and issuances of common stock could result in additional dilution of percentage ownership.
• Provisions in corporate charter documents and Delaware law could make a change in control more difficult.
• If securities or industry analysts do not publish or publish inaccurate/unfavorable research, stock price and trading volume could decline.
• No intention to pay dividends on capital stock for the foreseeable future.
• The consummation of the Business Combination is subject to conditions, and if not satisfied or waived, the combination may not be completed.
• Conflicts of interest among officers and directors of PCSC and Freenome may influence approval of the business combination.
• No assurance that sufficient capital will be raised in the PIPE Investment to consummate the business combination.
• The business combination is subject to a minimum net cash closing condition of $250 million.
• A portion of the total outstanding shares of the post-closing combined company will be restricted from immediate resale but may be sold into the market in the near future, causing price decline.
• PCSC's shareholders will experience immediate dilution due to the issuance of securities to Freenome security holders and PIPE investors.
• No assurances that PCSC will complete the business combination prior to its expiration date (September 5, 2026).
• Uncertainty of the value of merger consideration until closing.
• Substantial transaction fees and costs will be incurred, potentially higher than anticipated.
• Securities litigation or shareholder activism could negatively affect business or delay the combination.
• PCSC shareholders may purchase Class A ordinary shares from public shareholders, reducing public float.
• Proceeds in PCSC's trust account could be reduced by redemptions, leading to a lower per-share redemption amount.
• Nasdaq may delist PCSC's Class A ordinary shares or not list the combined company's securities.
• PIPE shares are not initially registered and cannot be transferred or resold without an exemption.
• No assurance that the combined company will comply with Nasdaq's continued listing standards.
• An active trading market for the combined company's common stock may not be consistently available, leading to price volatility.
• If analysts cease coverage or change recommendations, the stock price could decline.
• Benefits of the proposed business combination may not be realized as anticipated.
• The ability to recognize benefits may be affected by competition, growth management, customer/supplier relationships, and key employee retention.
• Changes to the board of directors composition may affect the combined company's strategy.
• Dependence on key personnel, with loss negatively impacting operations and profitability.
• Lack of experience operating as a public company subject to U.S. federal securities laws, potentially leading to compliance issues (Sarbanes-Oxley Act).
• Taking advantage of emerging growth company exemptions could make securities less attractive to investors.
• Requirements of being a public company may strain resources and distract management.
• Post-closing write-downs, restructuring, or impairment charges could significantly affect financial condition and stock price.
• Material weaknesses in internal control over financial reporting could lead to errors in financial reporting.
• Failure to maintain effective disclosure controls and internal controls could impair timely and accurate financial statements.
• Incorrect estimates or judgments relating to critical accounting standards could adversely affect results of operations.
• No underwriters involved in the process, potentially resulting in less diligence on Freenome.
• Significant redemptions could materially impact the combined company's cash position and runway.
• PCSC's public shareholders' redemption rights may prevent completion of the most desirable business combination or full funding of Freenome's plan.
• Past performance by PCSC's management team or affiliates may not be indicative of future performance.
• Combined company's governing documents may discourage takeover attempts.
• Freenome's operating and financial results presented to PCSC's board may not prove accurate.
• Activities by existing PCSC shareholders to increase approval likelihood could depress PCSC's share price.
• PCSC may be prohibited from certain beneficial transactions after executing the definitive agreement.
• Material adverse effects may result from the announcement of the business combination, industry-wide changes, and other causes.
• Delays in completing the business combination may substantially reduce expected benefits.
• Broad discretion in the use of cash on hand, which may not be used effectively.

Future Outlook

Freenome anticipates accelerating the development of its AI/ML-driven multiomics platform, expanding its commercial and data infrastructure to support the expected 2026 launch of multiple blood-based cancer detection tests (including colorectal cancer and lung), and advancing its personalized multi-cancer detection pipeline. The company aims to offer multiple tests tailored to individual health profiles, risk, and guideline eligibility, leveraging commercial partnerships to scale data generation for future test improvements and pipeline expansion. Key milestones include PMA approval for SimpleScreen CRC v1 in mid-2026, sPMA submission for SimpleScreen CRC v2 in 2H 2026, and LDT launches for Lung v1 and first-wave P-MCD in 2H 2026 and 1H 2027, respectively.

Management Comments

• "Freenome is entering the public markets at an inflection point for our company and for blood-based cancer screening." Aaron Elliott, Ph.D., CEO of Freenome.
• "Our technology has been clinically validated through our pivotal PREEMPT CRC study and recent JAMA manuscript. We have secured the commercialization partnerships needed to support the expected launch of multiple tests in 2026." Aaron Elliott, Ph.D., CEO of Freenome.
• "Perceptive Advisors and our other PIPE investors bring deep healthcare expertise and conviction in our approach to make multi-cancer detection personalized, accessible and part of routine care." Aaron Elliott, Ph.D., CEO of Freenome.
• "We founded PCSC to partner with transformational life sciences companies, and Freenome represents exactly the type of business we set out to support." Adam Stone, Chief Investment Officer of Perceptive Advisors and CEO of PCSC.
• "Freenome has built a leading platform, assembled top-tier strategic partners, and demonstrated a clear path toward making blood-based cancer screening broadly accessible. We are thrilled to partner with the Freenome team and to support the company through its next stage of growth." Adam Stone, Chief Investment Officer of Perceptive Advisors and CEO of PCSC.

Industry Context

The announcement positions Freenome at the forefront of the rapidly evolving early cancer detection market, which is projected to be a $50 billion opportunity. The company's multiomics, AI/ML-based platform aims to address the current limitations of cancer screening, where only about 14% of diagnosed cancers are detected by screening and nearly 50% are found at advanced stages. Freenome's strategy of starting with population-level colorectal cancer (CRC) screening, a large and reimbursed market with significant unmet need (40-50 million unscreened individuals in the U.S.), aligns with broader trends towards non-invasive, blood-based diagnostics. Strategic partnerships with established players like Exact Sciences and Roche are critical for accelerating market adoption, integrating into primary care, and expanding globally, reflecting a collaborative approach to innovation and commercialization in the diagnostics industry.

Comparison to Industry Standards

• SimpleScreen CRC v1's performance (64% overall CRC sensitivity, 81% Stage I CRC sensitivity, 14% Advanced Adenoma sensitivity, 31% High-Grade Dysplasia sensitivity at 90% specificity) is presented as potentially 'best-in-class' among blood-based tests, comparing favorably to Guardant Health's Shield v1 (55% overall CRC sensitivity, 83% Stage I CRC sensitivity, 13% Advanced Adenoma sensitivity at 90% specificity) and an unnamed 'Colon Cancer Blood Test' (73% overall CRC sensitivity at 90% specificity).
• SimpleScreen CRC v2, with anticipated sPMA submission in 2H 2026, shows improved performance (75% overall CRC sensitivity, 85% Stage I CRC sensitivity, 22% Advanced Adenoma sensitivity, 44% High-Grade Dysplasia sensitivity at 90% specificity) compared to v1 and Guardant Health's Shield v1, and also Guardant's Shield v2 (anticipated sPMA 2H 2025) which reports 62% overall CRC sensitivity at 90% specificity.
• Freenome's Lung v1 test achieved ~80% sensitivity at 75% specificity, which is comparable to the specificity of Low-Dose CT (LDCT) screening (>75%) for lung cancer, addressing a significant unmet need given low adherence rates (~10-15%) for LDCT in high-risk populations.
• The company's multiomics platform, combining DNA, proteins, RNA, and other analytes with AI/ML, is designed to overcome the limitations of single-omic assays and improve detection of early-stage cancers, a key differentiator in the competitive landscape of liquid biopsy companies.

Management Changes

Corporate Governance

Related Party Transactions

• Perceptive Capital Solutions Holdings (the Sponsor) and certain PCSC Insiders (Mark McKenna, Kenneth Song, Harlan Waksal) are parties to the Sponsor Letter Agreement, agreeing to vote in favor of the business combination and waive anti-dilution rights.
• Perceptive Life Sciences Master Fund Ltd (an affiliate of the Sponsor) and RA Capital Healthcare Fund, L.P. are among the PIPE Investors, committing $75 million to the PIPE financing.
• The Investor Rights Agreement will be entered into by New Freenome, the Sponsor, Perceptive, and certain Freenome Holders, granting registration rights.
• The Lock-Up Agreement will be entered into by New Freenome, the Sponsor, Perceptive, PCSC Existing Investors, and Company Existing Stockholders, restricting share transfers for six months.
• The PCSC Special Committee received a fairness opinion from Scalar, LLC regarding the Adjusted Transaction Share Consideration being fair to PCSC Class A shareholders (excluding certain related parties).

Stakeholder Impact

• **Shareholders (PCSC Public):** Will have the opportunity to redeem their Class A shares for cash or convert them into shares of the combined company. They will experience immediate dilution due to the issuance of securities to existing Freenome security holders and PIPE investors.
• **Shareholders (Freenome):** Will roll 100% of their equity into the combined company, becoming shareholders of the publicly traded Freenome, Inc., aligning their interests with the new entity's public market performance.
• **Employees:** Will benefit from new equity incentive and employee stock purchase plans, aligning their interests with the company's long-term success. The business combination is expected to accelerate product development and commercialization, potentially creating new opportunities.
• **Customers/Patients:** The transaction aims to accelerate the development and commercialization of blood-based cancer detection tests, potentially leading to earlier and more accessible cancer screening options.
• **Investors (PIPE):** Will acquire shares at $10.00 per share, providing significant capital to the combined company and gaining exposure to Freenome's growth potential.
• **Management:** The existing Freenome management team will lead the combined company, with a new board structure in place, maintaining continuity in strategic direction.
• **Regulatory Bodies:** The transaction involves significant regulatory filings and approvals (e.g., SEC, Nasdaq, HSR Act), ensuring compliance and transparency.

Next Steps

• PCSC to domesticate as a Delaware corporation and change its name to Freenome, Inc. at least one business day prior to closing.
• Merger Sub I to merge with Freenome, followed by the surviving entity merging into Merger Sub II, with Merger Sub II surviving as a wholly-owned subsidiary of New Freenome.
• PCSC to file a Registration Statement on Form S-4 with the SEC, including a preliminary proxy statement and prospectus, and seek effectiveness.
• PCSC to convene an extraordinary general meeting of shareholders to obtain approval for the business combination and related proposals.
• Freenome to obtain written consent from its stockholders approving the business combination.
• PIPE Investors to deliver $240 million in gross proceeds to an escrow account prior to closing.
• New Freenome, Sponsor, and certain Freenome stockholders to enter into an Investor Rights Agreement and a Lock-Up Agreement at closing.
• New Freenome to file a registration statement for the resale of PIPE shares within 30 calendar days after the Closing Date.
• New Freenome to approve and adopt an Equity Incentive Plan and an Employee Stock Purchase Plan prior to the effectiveness of the Registration Statement/Proxy Statement.
• Anticipated PMA Approval & IVD Launch for SimpleScreen CRC v1 in mid-2026.
• Anticipated CMS Coverage for SimpleScreen CRC v1 in 2026.
• Anticipated sPMA Submission for SimpleScreen CRC v2 in 2H 2026.
• Anticipated LDT Launch for Lung v1 in 2H 2026.
• Anticipated P-MCD Multiomics Readout v1 in 1H 2027.
• Anticipated First Wave P-MCD LDT Launch in 1H 2027.
• Anticipated USPSTF Guidelines for SimpleScreen CRC v1 in 2027.

Key Dates

Keywords

Freenome, Perceptive Capital Solutions Corp, PCSC, SPAC, Business Combination, Merger, Cancer Detection, Blood Test, Multiomics, AI/ML, Colorectal Cancer Screening, CRC, PIPE Financing, Nasdaq Listing, Exact Sciences, Roche, Healthcare, Biotechnology, Diagnostics, Medical Devices, Clinical Trials, Regulatory Approval, FRNM